In vitro suppression of immune responses using monocyte-derived tolerogenic dendritic cells from patients with primary Sjögren's syndrome

Arthritis Research and Therapy

Volumn 15, Issue 5, 2013, Pages

  Volchenkov, Roman ^a   Brun, Johan G ^a,b   Jonsson, Roland ^a,b   Appel, Silke ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

dendritic cells; immunotherapy; Ro La specific T cell suppression; Sj gren's syndrome

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; COLECALCIFEROL; CXCL9 CHEMOKINE; DEXAMETHASONE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; T6 ANTIGEN; AUTOANTIGEN; CYTOKINE; RIBONUCLEOPROTEIN; SS A ANTIGEN; SS B ANTIGEN; SS-A ANTIGEN; SS-B ANTIGEN; VITAMIN;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; AUTOLOGOUS MIXED LYMPHOCYTE REACTION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; PHENOTYPE; SJOEGREN SYNDROME; AGED; BLOOD; CELL CULTURE; COCULTURE; DRUG EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MIXED LYMPHOCYTE CULTURE; T LYMPHOCYTE;

ADULT; AGED; AUTOANTIGENS; CELLS, CULTURED; CHOLECALCIFEROL; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; DEXAMETHASONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNE TOLERANCE; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; MONOCYTES; RIBONUCLEOPROTEINS; SJOGREN'S SYNDROME; T-LYMPHOCYTES; VITAMINS;

EID: 84883650305     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4294     Document Type: Article

References (37)

1. Jonsson R, Vogelsang P, Volchenkov R, Espinosa A, Wahren-Herlenius M, Appel S. The complexity of Sjogren's syndrome: novel aspects on pathogenesis. Immunol Lett 2011, 141:1-9.
2. Volchenkov R, Jonsson R, Appel S. Anti-Ro and anti-La autoantibody profiling in Norwegian patients with primary Sjogren's syndrome using luciferase immunoprecipitation systems (LIPS). Scand J Rheumatol 2012, 41:314-315.
3. Brito-Zeron P, Siso-Almirall A, Bove A, Kostov BA, Ramos-Casals M. Primary Sjogren syndrome: an update on current pharmacotherapy options and future directions. Expert Opin Pharmacother 2013, 14:279-289.
4. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puechal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004, 50:1270-1276.
5. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot J-M, Perdriger A. Tolerance and efficacy of rituximab in primary Sjogren's syndrome: final results of a randomized controlled trial. Arthritis Rheum 2012, 64:S1079.
6. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
7. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000, 191:411-416.
8. Liu YJ. A unified theory of central tolerance in the thymus. Trends Immunol 2006, 27:215-221.
9. Thomson AW, Robbins PD. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann Rheum Dis 2008, 67(Suppl 3):iii90-96.
10. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007, 7:610-621.
11. Anderson AE, Swan DJ, Sayers BL, Harry RA, Patterson AM, von Delwig A, Robinson JH, Isaacs JD, Hilkens CM. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol 2009, 85:243-250.
12. Volchenkov R, Karlsen M, Jonsson R, Appel S. Type 1 regulatory T cells and regulatory B cells induced by tolerogenic dendritic cells. Scand J Immunol 2013, 77:246-254.
13. Stoop JN, Harry RA, von Delwig A, Isaacs JD, Robinson JH, Hilkens CM. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum 2010, 62:3656-3665.
14. Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010, 69:2042-2050.
15. Raiotach-Regue D, Grau-Lopez L, Naranjo-Gomez M, Ramo-Tello C, Pujol-Borrell R, Martinez-Caceres E, Borras FE. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol 2012, 42:771-782.
16. Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, Tsuzaka K, Ogawa Y, Tsubota K, Abe T, Takeuchi T. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren's syndrome. Arthritis Res Ther 2011, 13:R170.
17. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, . European Study Group on Classification Criteria for Sjogren's S Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558. European Study Group on Classification Criteria for Sjogren's S.
18. Fedele G, Frasca L, Palazzo R, Ferrero E, Malavasi F, Ausiello CM. CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction. Eur J Immunol 2004, 34:1342-1350.
19. Frasca L, Fedele G, Deaglio S, Capuano C, Palazzo R, Vaisitti T, Malavasi F, Ausiello CM. CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells. Blood 2006, 107:2392-2399.
20. Ma L, Mauro C, Cornish GH, Chai JG, Coe D, Fu H, Patton D, Okkenhaug K, Franzoso G, Dyson J, Nourshargh S, Marelli-Berg FM. Ig gene-like molecule CD31 plays a nonredundant role in the regulation of T-cell immunity and tolerance. Proc Natl Acad Sci USA 2010, 107:19461-19466.
21. Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, Ornetti P, Maillefert JF, Miossec P, Bonnotte B. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012, 64:2499-2503.
22. Ryba-Stanislawowska M, Skrzypkowska M, Mysliwska J, Mysliwiec M. The serum IL-6 profile and Treg/Th17 peripheral cell populations in patients with type 1 diabetes. Mediators Inflamm 2013, 2013:205284.
23. Lee DG, Woo JW, Kwok SK, Cho ML, Park SH. MRP8 promotes Th17 differentiation via upregulation of IL-6 production by fibroblast-like synoviocytes in rheumatoid arthritis. Exp Mol Med 2013, 45:e20.
24. Tanaka T, Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 2012, 8:1227-1236.
25. Morgan ME, van Bilsen JH, Bakker AM, Heemskerk B, Schilham MW, Hartgers FC, Elferink BG, van der Zanden L, de Vries RR, Huizinga TW, Ottenhoff TH, Toes RE. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol 2005, 66:13-20.
26. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD, Rudensky AY. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006, 103:6659-6664.
27. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007, 37:129-138.
28. Gregori S, Goudy KS, Roncarolo MG. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 2012, 3:30.
29. Wechsler AS, Gordon MC, Dendorfer U, LeClair KP. Induction of IL-8 expression in T cells uses the CD28 costimulatory pathway. J Immunol 1994, 153:2515-2523.
30. Gesser B, Lund M, Lohse N, Vestergaad C, Matsushima K, Sindet-Pedersen S, Jensen SL, Thestrup-Pedersen K, Larsen CG. IL-8 induces T cell chemotaxis, suppresses IL-4, and up-regulates IL-8 production by CD4+ T cells. J Leukoc Biol 1996, 59:407-411.
31. Sugimoto A, Suzuki M, Otani T, Okochi A, Takeuchi M, Yamasaki F, Nakamura S, Kibata M. HOZOTs, novel human regulatory T-cell lines, exhibit helper or suppressor activities depending on dendritic cell or anti-CD3 stimulation. Exp Hematol 2009, 37:1454-1463.
32. Harashima A, Toraya T, Okochi A, Yamamoto M, Suzuki M, Otani T, Inoue T, Tsuji-Takayama K, Sugimoto A, Takeuchi M, Yamasaki F, Nakamura S, Kibata M. Interleukin-8 and RANTES are signature cytokines made by HOZOT, a new type of regulatory T cells. Mol Immunol 2009, 46:3310-3319.
33. Himmel ME, Crome SQ, Ivison S, Piccirillo C, Steiner TS, Levings MK. Human CD4+ FOXP3+ regulatory T cells produce CXCL8 and recruit neutrophils. Eur J Immunol 2011, 41:306-312.
34. Stoop JN, Robinson JH, Hilkens CM. Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models?. Ann Rheum Dis 2011, 70:1526-1533.
35. Haldorsen K, Moen K, Jacobsen H, Jonsson R, Brun JG. Exocrine function in primary Sjogren syndrome: natural course and prognostic factors. Ann Rheum Dis 2008, 67:949-954.
36. Jonsson MV, Hammenfors D, Brun JG, Jonsson R. Ultrasonography of major salivary glands in primary Sjogren's syndrome. Arthritis Rheum 2012, 64:S925.
37. Zou Q, Jiao J, Zou MH, Xu JH, Pan YF, Chen JN, Cheng MH, Zhang F, Zhang Y. Semi-quantitative evaluation of salivary gland function in Sjogren's syndrome using salivary gland scintigraphy. Clin Rheumatol 2012, 31:1699-1705.